Case Reports

Permanent URI for this collection

http://hdl.handle.net/2003/36298

News

Editors

  • J. G. Hengstler
    Leibniz Research Centre for Working Environment and Human Factors
    Ardeystr. 67
    D-44139 Dortmund
    Germany

Editorial Board

Address & Contact:

Susanne Lindemann
Managing editor/EXCLI Journal
Leibniz Research Centre for Working Environment and Human Factors
Ardeystraße 67
D-44139 Dortmund
Germany
Fon +49 231 1084 251

Browse

Recent Submissions

Now showing 1 - 1 of 1
  • Thumbnail Image
    Item
    Avelumab inducing hypothyroidism and hypoadrenalism
    (2018-06-06) Aziz, Kashif; Shahbaz, Amir; Umair, Muhammad; Sachmechi, Isaac
    Avelumab is an anti-PD-L1 (programmed death-ligand 1) immune checkpoint inhibitor (ICIs) and the monoclonal antibody that constitutes a major development in the immunotherapy of cancer. In 2017, The European Medicine Agency (EMA) approved it as an orphan drug for treatment of gastric cancer. Avelumab has recently been approved in the United States, Europe and Japan for treatment of metastatic Merkel cell carcinoma (MCC). Avelumab inhibits the interaction of Programmed cell death protein 1 (PD-1) on immune cells with PD-L1 on tumor cells, thus banishing immunosuppressive signals and leading to enhanced immune cell activation. Here we are revealing a case of the patient with metastatic gastric cancer receiving avelumab with the development of undesirable endocrinopathies during the course of treatment. We suggested that patients receiving avelumab immunotherapy should be monitored for signs and symptoms of thyroiditis, hypothyroidism and adrenal insufficiency, which may require immediate attention and supportive treatment by immunosuppression and respective hormone replacement.